251 related articles for article (PubMed ID: 35804621)
1. Is the Use of Bisphosphonates Putting Horses at Risk? An Osteoclast Perspective.
Vergara-Hernandez FB; Nielsen BD; Colbath AC
Animals (Basel); 2022 Jul; 12(13):. PubMed ID: 35804621
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
3. Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass.
Yuan H; Niu LN; Jiao K; Pei DD; Pramanik C; Li JY; Messer R; Kumar S; Pashley DH; Tay FR
Acta Biomater; 2016 Feb; 31():312-325. PubMed ID: 26678828
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate use in the horse: what is good and what is not?
Mitchell A; Watts AE; Ebetino FH; Suva LJ
BMC Vet Res; 2019 Jun; 15(1):211. PubMed ID: 31234844
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know.
Allen MR; Burr DB
Bone; 2011 Jul; 49(1):56-65. PubMed ID: 20955825
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
7. On the pharmacological evaluation of bisphosphonates in humans.
Cremers S; Ebetino FH; Phipps R
Bone; 2020 Oct; 139():115501. PubMed ID: 32599224
[TBL] [Abstract][Full Text] [Related]
8. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors.
Vermeer JA; Jansen ID; Marthi M; Coxon FP; McKenna CE; Sun S; de Vries TJ; Everts V
Bone; 2013 Nov; 57(1):242-51. PubMed ID: 23962725
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
10. Abundant osteoclasts in the subchondral bone of the juvenile Thoroughbred metacarpus suggest an important role in joint maturation.
Gilday R; Richard H; Beauchamp G; Fogarty U; Laverty S
Equine Vet J; 2020 Sep; 52(5):733-742. PubMed ID: 31972056
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in veterinary medicine: The new horizon for use.
Suva LJ; Cooper A; Watts AE; Ebetino FH; Price J; Gaddy D
Bone; 2021 Jan; 142():115711. PubMed ID: 33141069
[TBL] [Abstract][Full Text] [Related]
12. The Role Of BMPs in the Regulation of Osteoclasts Resorption and Bone Remodeling: From Experimental Models to Clinical Applications.
Bordukalo-Nikšić T; Kufner V; Vukičević S
Front Immunol; 2022; 13():869422. PubMed ID: 35558080
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate mechanism of action.
Rodan GA; Reszka AA
Curr Mol Med; 2002 Sep; 2(6):571-7. PubMed ID: 12243249
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
15. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
[TBL] [Abstract][Full Text] [Related]
16. PTH(1-34) Treatment Increases Bisphosphonate Turnover in Fracture Repair in Rats.
Murphy CM; Schindeler A; Cantrill LC; Mikulec K; Peacock L; Little DG
J Bone Miner Res; 2015 Jun; 30(6):1022-9. PubMed ID: 25484198
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
18. Rationale for the use of bisphosphonates in bone metastases.
Kanis JA; McCloskey EV; Taube T; O'Rourke N
Bone; 1991; 12 Suppl 1():S13-8. PubMed ID: 1954047
[TBL] [Abstract][Full Text] [Related]
19. The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study.
Gossiel F; Hoyle C; McCloskey EV; Naylor KE; Walsh J; Peel N; Eastell R
Bone; 2016 Nov; 92():94-99. PubMed ID: 27535783
[TBL] [Abstract][Full Text] [Related]
20. Giant osteoclasts in patients under bisphosphonates.
Mac-Way F; Trombetti A; Noel C; Lafage-Proust MH
BMC Clin Pathol; 2014; 14():31. PubMed ID: 25024641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
